348 related articles for article (PubMed ID: 35975555)
1. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
[TBL] [Abstract][Full Text] [Related]
2. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI
J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
5. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
6. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
7. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
[TBL] [Abstract][Full Text] [Related]
8. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.
Swainson J; McGirr A; Blier P; Brietzke E; Richard-Devantoy S; Ravindran N; Blier J; Beaulieu S; Frey BN; Kennedy SH; McIntyre RS; Milev RV; Parikh SV; Schaffer A; Taylor VH; Tourjman V; van Ameringen M; Yatham LN; Ravindran AV; Lam RW
Can J Psychiatry; 2021 Feb; 66(2):113-125. PubMed ID: 33174760
[TBL] [Abstract][Full Text] [Related]
9. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
[TBL] [Abstract][Full Text] [Related]
10. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Leger RF; Unterwald EM
J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
[TBL] [Abstract][Full Text] [Related]
11. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
Pearson C; Siegel J; Gold JA
J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
[TBL] [Abstract][Full Text] [Related]
12. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
13. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of psychedelic medicine: current status and future directions.
Wsół A
Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.
Andersen KAA; Carhart-Harris R; Nutt DJ; Erritzoe D
Acta Psychiatr Scand; 2021 Feb; 143(2):101-118. PubMed ID: 33125716
[TBL] [Abstract][Full Text] [Related]
16. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
[TBL] [Abstract][Full Text] [Related]
17. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
[TBL] [Abstract][Full Text] [Related]
18. Classical psychedelics for the treatment of depression and anxiety: A systematic review.
Muttoni S; Ardissino M; John C
J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100
[TBL] [Abstract][Full Text] [Related]
19. Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.
Prouzeau D; Conejero I; Voyvodic PL; Becamel C; Abbar M; Lopez-Castroman J
Curr Psychiatry Rep; 2022 Oct; 24(10):573-581. PubMed ID: 35953638
[TBL] [Abstract][Full Text] [Related]
20. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
Ko K; Kopra EI; Cleare AJ; Rucker JJ
J Affect Disord; 2023 Feb; 322():194-204. PubMed ID: 36209780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
